Global biotechnology leader CSL Behring today announced that the European Commission has granted conditional marketing authorization (CMA) for HEMGENIX® (etranacogene dezaparvovec).
First Gene Therapy for Hemophilia B, CSL Behring’s HEMGENIX®, Approved by the European Commission
Approval of HEMGENIX® underscores CSL’s promise to deliver life-changing innovations that have the potential to help patients lead full lives.
